Heavy chain composition: IgG1 antibodies contain two heavy chains with constant (Cγ1), hinge, and variable regions .
Effector functions: IgG1 engages activating Fcγ receptors (FcγRIIA, FcγRI) and complements (C1q), enabling antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) .
Glycosylation: Critical for FcγR binding; mutations like N297A abolish effector functions .
Target: Gamma-aminobutyric acid receptor γ1 subunit, critical for inhibitory neurotransmission .
Applications:
FcγR Engagement: Antibodies like anti-GITR (DTA-1) require activating FcγRs (e.g., FcγRIII) for antitumor efficacy, as shown in murine models .
Effector-Attentuation: Mutations (e.g., LALA-PG) in IgG1 Fc regions reduce complement binding (C1q) by >50% while maintaining stability .
Genetic Diversity: Polymorphisms in IgG1 constant domains (e.g., G1m allotypes) influence effector functions and therapeutic efficacy .
| Antibody | Target Pathway | Host/Isotype | Key Application | Therapeutic Area |
|---|---|---|---|---|
| AMPK Gamma 1 (67182-1-Ig) | Metabolic regulation | Mouse IgG1 | Western blot, ELISA | Cancer, Diabetes |
| GABA A γ1 (ab74327) | Neurotransmission | Rabbit IgG | Immunofluorescence | Neurological disorders |
| PLCγ1 (ab302941) | Cell signaling | Mouse IgG1 | WB, ICC/IF | Oncology |